- GlobeNewswire•27 days agoMedigene AG: bluebird bio and Medigene establish strategic T cell receptor (TCR) alliance in cancer immunotherapy
T cell receptor (TCR) therapeutic candidates against four targets to be generated using Medigene`s proprietary TCR technology platform and bluebird bio`s lentiviral vector, genome editing, synthetic biology, ...
- GlobeNewswire•last month
Martinsried/Munich, 26 September 2016. Medigene AG (MDG1, Frankfurt, Prime Standard) announces its participation at five upcoming national and international scientific, investor and business development ...
- GlobeNewswire•last monthMedigene publicizes new bioinformatics tool to predict potential cross-reactivity of cancer and virus antigens
Article in "Bioinformatics" published in collaboration with scientists from Technical University of Munich and Helmholtz Zentrum München Martinsried/Munich, 16 September 2016. Medigene AG (MDG1, ...
MEDIGENE AG NA O.N. (MDG1.HA)
Hanover - Hanover Delayed Price. Currency in EUR
At close: 2:10 AM EDT
|Bid||0.00 x 40000|
|Ask||0.00 x 29000|
|Day's Range||6.80 - 6.80|
|52wk Range||5.45 - 11.45|
|1y Target Est||N/A|
|P/E Ratio (ttm)||N/A|
|Avg Vol (3m)||17|
|Dividend & Yield||N/A (N/A)|